Young Discusses New Requirements On Federally Funded Duke University Medical Researchers
26 March 2018
Senior Counsel Torrey Young was quoted in a Durham Herald Sun article, “The feds are keeping a closer eye on Duke research grants. Why?” about the imposition of new National Institutes of Health requirements on university-based medical research in response to concerns about Duke’s handling of several recent research misconduct cases.
Young said the significance of the move is that the NIH, which funds tens of millions of dollars’ worth of medical research at Duke each year, seems worried about more than just a few individual bad actors.
“It’s a call for making sure the entire process is being overseen by the university, which is the ultimate recipient of the grant funds,” she said. “Historically, a lot of research misconduct cases have focused on the individual investigator. This is drawing more attention to institutional processes.”
Young said the significance of the move is that the NIH, which funds tens of millions of dollars’ worth of medical research at Duke each year, seems worried about more than just a few individual bad actors.
“It’s a call for making sure the entire process is being overseen by the university, which is the ultimate recipient of the grant funds,” she said. “Historically, a lot of research misconduct cases have focused on the individual investigator. This is drawing more attention to institutional processes.”
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”